AVIR Stock Analysis: Buy, Sell, or Hold?
AVIR - Atea Pharmaceuticals, Inc. Common Stock
$4.27
-0.30 (-6.56%)
▼
5d:
-22.92%
30d:
-27.38%
90d:
-1.39%
WAIT
LOW Confidence
Analysis Updated: May 14, 2026 12:00 AM ET
Earnings: May 12, 2026
0d
Get Alerted When AVIR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: AVIR is down 22.9% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: AVIR is down 22.9% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: AVIR is currently trading at $4.27, which is considered oversold relative to its 30-day fair value range of $5.20 to $5.90.
Technical Outlook: Technically, AVIR is in a strong uptrend. The price is currently testing key support at $4.20. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 6.6% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $8.83 (+106.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, AVIR is in a strong uptrend. The price is currently testing key support at $4.20. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 6.6% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $8.83 (+106.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$5.20 -
$5.90
Company Quality Score
51/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-6.6%)
- BULLISH: Trading 106.9% below Wall St target ($8.83)
- WARNING: Recommendation downgraded due to -22.9% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$5.20 -
$5.90
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$4.20
Resistance Level
$5.83
Current Trend
Strong Uptrend
Technical data as of
May 14, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-3.08
Wall Street Target
$8.83
(+106.9%)
Revenue Growth (YoY)
295.2%
Earnings Growth (YoY)
264.1%
Share & Embed Analysis
Last updated: May 14, 2026 8:17 PM ET
Data refreshes hourly during market hours. Next update: 9:17 PM
Data refreshes hourly during market hours. Next update: 9:17 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is AVIR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$57 | 62 BUY |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$550 | 64 BUY |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$875 | 63 BUY |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$53 | 61 BUY |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$79 | 60 BUY |